University of Central Florida Undergraduate Research Journal - Analysis of the Pathomechanism and Treatment of Migraines Related to the Role of the Neuropeptide CGRP
US tab

References

  1. Headache Classification Subcommittee of the International Headache Society, The International Classification of Headache Disorders, Cephalagia, 2004, 24, 1.
  2. Samsam, Mohtashem. "Role of Neuropeptides in Migraine Headaches, Experimental and Clinical Data." Transworld Research Network (2007): 274-98.
  3. Wolff, H.G. 1943, Pain, Research Publication Association of Research and Nervous and Mental Diseases, 23, William & Wilkins, Baltimore.
  4. Samsam, Mohtashem. "Central Nervous System Acting Drugs in Treatment of Migraine Headache." Central Nervous System Agents in Medicinal Chemistry 2012, 12.3, 158-72.
  5. Weiller, C.; May, A.; Limmroth, V.; Juptner, M.; Kaube, H. "Brain stem activation in spontaneous human migraine attacks." Nat. Med., 1995, 1, 658-660.
  6. Bahra, A.; Matharu, M.S. "Brainstem activation specific to migraine headache." Lancet, 2001, 357, 10161017.
  7. Cohen, A.S.; Goadsby, P.J. "Functional neuroimaging of primary headache disorders." Expert Rev. Neurother., 2006, 6, 1159-1171.
  8. Geraud, G.; Denuelle, M.; Fabre, N. "Positron emission tomographic studies of migraine." Rev. Neurol. Paris, 2005, 161, 666-670.
  9. Welch, K.M., Nagesh, V. "Periaqueductal gray matter dysfunction in migraine: cause or the burden of illness?" Headache, 2001, 41, 629-597.
  10. D'Andrea, G. and Leon, A. "Pathogenesis of migraine: from neurotransmitters to neuromodulators and beyond." Neurological Sciences, 2010, 31 Suppl 1: S17.
  11. G. D'Andrea. "Pathogenesis of migraine: from neurotransmitters to neuromodulators and beyond." Neurological Sciences, 06/2010.
  12. Moskowitz, M.A. 1984, "The neurobiology of vascular head pain." Ann. Neurol., 16, 157.
  13. Sandor, P., Afra, J., Proietti Cecchini, A., Albert, A., and Schoenen, J. "Evaluation and Proposal for Optimalization of Neurophysiological Tests in Migrain: Part 1—Electrophysiological Tests" 2005, Funct. Neuro., 3, 68.
  14. Linde, M., and Dahlf, C. "The acute and preventative treatment of episodic migraine" Rev. Ser. Neurol., 2002, 4, 8.
  15. De Vries P, Villalon CM, Saxena PR.. "Pharmacological aspects of experimental headache models in relation to acute antimigraine therapy." Eur J Pharmacol 1999, 375, 61-74.
  16. Troost BT, Mark LE, Maroon JC. "Resolution of classic migraine after removal of occipital lobe AVM." Ann. Neurol 1979, 5,199-201.
  17. Ophoff RA, Van den Maagddenberg AM, Room KI, Ferrari MD. "The impact of pharmacogenetics for migraine." Eur J Pharmacol 2001, 413, 1-10.
  18. U Arulmani. "Experimental migraine models and their relevance in migraine therapy." Cephalagia, 6/2006.
  19. Van der Maagdenberg, A.M.; Pietrobon, D.; Pizzorusso. "A Cacn1a knocking migraine mouse model with increase susceptibility to cortical spreading depression." Neuron, 2004, 41, 701-710.
  20. Blau, J. "Migraine prodromes separated from the aura: complete migraine." Br. Med. J., 1980, 281, 658.
  21. Weiller, C., May, A., Limmroth, V., Juptner, M., Diener, H.C. "Brain stem activation in spontaneous human migraine attacks." Nat. Med., 1995, 1, 658.
  22. Rammussen, B. K.; Olesen, J. "Migraine with aura and migraine without aura: an epidemiological study." Cephalagia, 1992, 12, 221-228.
  23. Lauritezen, M. "Cortical spreading depression in migraine." Cephalagia, 2001, 21, 757-760.
  24. Leibowitz, D. "The glial spike theory. I. On an active role of neuroglia in spreading depression and migraine." Proc. Biol. Sci., 1992, 250, 287.
  25. Goadsby, P.J. "Another migraine gene." Lancet, 2005, 366, 345-6.
  26. Ayata, C.; Jin, H.; Kudo, C.; "Supression of cortical spreading depression in migraine prophylaxis." Ann. Neurol., 2006, 59, 652-61.
  27. Samsam, Mohtashem. "Editorial [Hot Topic: Role of Inflammation in Neurological and Psychiatric Disorders (Guest Editor: Mohtashem Samsam)]." Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 2010, 9.3, 166-69.
  28. Samsam, M., R. Coveñas, R. Ahangari, J. Yajeya, and J.a. Narváez. "Role of Neuropeptides in Migraine: Where Do They Stand in the Latest Expert Recommendations in Migraine Treatment?" Drug Development Research 2007, 68.6, 294-314.
  29. Olesen, J.; Bonica, J.J. In: The Management of Pain, J.J. Ed., 1990, 1, 687-726.
  30. Asghar, M.S., Hansen, A.E., Olesen, J. "Dilation by CGRP of middle meningeal artery and reversal by sumatriptan in normal volunteers." Neurology, 2010, 75, 1520-6.
  31. Greves, L.E., Nyberg, F., Terenius, L. and Hokfelt, T. "Calcitonin gene-related peptide is a potent inhibitor of substance P degradation." Eur. J. Pharmacol., 1985, 115, 309.
  32. McLatchie LM, Fraser NK, Main MJ, Wise A, Brown J, Thompson N, Solari R, Lee MG, Foord SM. "RAMPs regulate the transport and ligand specificity of the calcitonin-receptor like receptor." Nature 1998, 393:333-339.
  33. Zhang Z, Winborn CS, Marquez de Prado B, Russo AF. "Sensitization of calcitonin gene-related peptide receptors by receptor activity-modifying protein-1 in the trigeminal ganglion." J Neurosci 2007, 27, 2693-2703.
  34. Benemei, Silvia, Francesco De Cesaris, Camilla Fusi, Eleonora Rossi, Chiara Lupi, and Pierangelo Geppetti. "TRPA1 and Other TRP Channels in Migraine." The Journal of Headache and Pain 2013, 14.1, 71.
  35. "Calcitonin gene-related peptide (CGRP) receptor antagonists in the treatment of migraine." National Center for Biotechnology Information. U.S. National Library of Medicine, 2015.
  36. Messlinger K, Suzuki A, Pawlak M, Zehnter A, Schmidt RF. "Involvement of nitric oxide in the modulation of dural arterial blood flow in the rat." Br J Pharmacol 2000, 129, 1397-1404.
  37. Thomsen, L.L.; Olesen, J. "Nitric oxide in primary headaches." Curr. Opin. Neurol., 2001, 14, 315-321.
  38. Messlinger, K.l Suzuki, A; Pawlak, M.; Zehnter, A.; Schmidt, R.F. "Involvement of nitric oxide in the modulation of dural arterial blood flow in the rat." Br. J. Pharmacol., 2000, 129, 1397-1404.
  39. Akerman, S.; Williamson, D.J., Kaube, H., Goadsby, P.J., "Nitric oxide synthase inhibitors can antagonize neurogenic and calcitonin gene-related peptide induced dilation of dural meningeal vessels." Br. J. Pharmacol., 2002, 137, 62-68.
  40. Gupta S, Mehrotra S, Villalon Cm. Peusquia M, Saxena PR, MaassenVanDenBrink A. "Potential role of female sex hormones in the pathophysiology of migraine." Pharmacol Ther 2007, 113, 321-340.
  41. Basbaum A I, Woolf, CJ. "Pain." Curr Biol 1999, 9, R429-R431.
  42. Knyihar-Csollik, E.; Tajiti, J.; Samsam, M.; Sary, G. "Electrical stimulation of the Gasserian ganglion induces structural alterations of calcitonin gene-related peptide Immunoreactive perivascular sensory nerve terminals in the rat cerebral dura mater: a possible model of migraine headache." Neurosci. Lett., 1995, 184, 189-192.
  43. Richter, F.; Mikulik, O.; Ebersberger, A; Schaible, H.G. "Noradrenergic agonists and antagonists influence migration of cortical spreading depression in rat-a possible mechanism of migraine prophylaxis and prevention of postischemic neuronal damage." J. Cereb. Blood Flow Metab., 2005, 25, 1225-35.
  44. Ziegler, D.K., Hurwitz, A., Preskorn, S., Hassanein, R., and Seim, J. "Propranolol and amitriptyline in prophylaxis of migraine. Pharmocokinetic and therapeutic effects." Arch. Neurol., 1993, 50, 825.
  45. Goadsby PJ, Edvinsson L. "The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats." Ann Neurol 1993, 33, 48-56.
  46. Cipolls, G.. Sacco, S., Crema, F., Moro, E., De Ponti, F., and Frigo, G. "Gastic motor effects of trptans: open questions and future perspectives." Pharmacol. Res., 2001, 43, 205.
  47. Olesen, J., Diener, H.C., Schoenen, J., and Hettiarachchi, J. "No effect of eletriptan administration during the aura phase of migraine." Eur J Neurol., 2004, 11, 671.
  48. Evers, S., Afra, J., Frese, A., Goadspby, P.J., Linde, M., May, A., and Sandor, P.S. "EFNS guideline on the drug treatment of migraine–revised report of an EFNS tast force." Eur. J. Neurol., 2006, 13, 560.
  49. Linde, M., Mellber, A., and Dahlof, C. Cephalagia, 2006, 26, 113.
  50. Longmore, J., Razzaque, Z., Shaw, D., Davenport, A.P., Maguire, J., Pickard, J.D., Schofield, W.N., and Hill, R.G. "Comparison of the vasoconstrictor effects of rizatriptan and sumatriptan in human isolated cranial arteries: immunohistological demonstration of the involvement of 5-HT1B-receptors." Br. J. Clin. Pharmacol., 1998, 46, 577.
  51. Howland, R.D., and Mycek, M.J. Pharmacology, R.A. Harvey, P.C. Champe (Eds.), Lippincott Williams & Wilkins, Philadelphia, 2006, 521.
  52. Melchart, D., Weidenhammer, W., Streng, A., Hoppe, A., Pfaffenrath, V., and Linde, K. "Acupuncture for chronic headaches—an epidemiological study." Headache, 2006, 46, 592.
  53. Bigal, M.E.; Serrano, D.; Buse, D.; Scher, A.; Stewart, W.F.; Lipton, R.B. "Acute migraine medications and evolution from episodic to chronic migraine: a longitudinal population-based study." Headache, 2008, 48, 1157-68.
  54. Cutrer FM. "Antiepileptic drugs:how they work in headache." Headache 2001, 41, S3-S10.
  55. Silberstein, S.D.; Lipton, R.B.; Dodick, D.W.; Freitag, F.G.; Ramadan, N.; Mathew, N.; Brandes, J.L.; Bigal, M.; Saper, J.; Ascher, S.; Jordan, D.M.; Greenberg, S.J.; Hulihan, J. "Topiramate Chronic Migraine Study Group. Efficacy and safety of topiramate for the treatment of chromic migraine: a randomized, double blind, placebocontrolled trial." Headache, 2007, 47, 170-80.
  56. Durham, P.L.; Niemann, C.; Cady, R. "Repression of stimulated calcitonin gene-related peptide secretion by topiramate." Headache, 2006, 46, 1291-5.
  57. Doods H, Hallermayer G, Wu D, Entzeroth M, Rudolf K, Engel W, Eberlein W. "Pharmacological profile pof BIBN4096BS, the first selective small molecule CGRP antagonist." Br K Pharmacol 2000, 129, 420-423.
  58. Storer RJ, Akerman S, Goadsby PJ. "Calcitonn gene-related peptide (CGRP) modulates nociceptive trigeminovascular transmission in the cat." Br J Pharmacol 2004, 142, 1171-1181.
  59. Fishcher MJ, Koulchitsky S, Messlinger K. "The nonpeptide calcitonin gene-related peptide receptor antagonist BIBN4096BS lowers the activity of neurons with meningeal input in the rat spinal trigeminal nucleus." J Neurosci 2005, 25, 5877-5883.
  60. Diener, H.C., Jansen, J.P., Reeches, A., Pascual, J, J., Pitei, D., and Steiner, T.J. "Identification of Negative Predictors of Pain-Free REsponse to Triptans: Analysis of the Electriptan Database." Eur. Neurol., 2002, 47, 99.
  61. Knyihár-Csillik, Elizabeth, János Tajti, Mohtasham Samsam, Gyula Sáry, Sándor Slezák, and László Vécsei. "Effect of a Serotonin Agonist (sumatriptan) on the Peptidergic Innervation of the Rat Cerebral Dura Mater and on the Expression of C–fos in the Caudal Trigeminal Nucleus in an Experimental Migraine Model." Journal of Neuroscience Research 1997, 48.5, 449-64.